MUMBAI, March 14 India's largest drugmaker Sun
Pharmaceutical Industries Ltd said on Tuesday that U.S.
regulators plan to lift a ban on its Mohali plant in northern
India, allowing the company to restart supplies from there after
Sun gained the plant along with its acquisition of Ranbaxy
Laboratories in 2015 and has been attempting to fix quality
control problems there that the U.S. Food and Drug
Administration (FDA) identified in 2013.
Sun said the FDA informed it on Monday that it plans to lift
the ban. "This proposed action will clear the path for Sun
Pharma to supply approved products from the Mohali facility to
the US market, subject to normal US FDA regulatory
requirements," the company said in a statement to stock
Sun's shares were up 6 percent at 722 rupees at 822 GMT in
Mumbai on Tuesday.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Muralikumar